Meeting
2017 Gastrointestinal Cancers Symposium
A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).
Authors
Maeve Aine Lowery
Memorial Sloan Kettering Cancer Center, New York, NY
Maeve Aine Lowery , Eileen Mary O'Reilly , James J. Harding , Kenneth H. Yu , Andrea Cercek , Ellen Hollywood , Erica Salehi , Ezra Margona , Mikaela Bradley , Trevor Witter , Scott R. Gerst , Marinela Capanu , Leonard Saltz , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01828034
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 290)
DOI
10.1200/JCO.2017.35.4_suppl.290
Abstract #
290
Poster Bd #
D4
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
First Author: Richard S. Finn
Poster
2023 ASCO Annual Meeting
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
First Author: Vaibhav Sahai
Poster
2014 ASCO Annual Meeting
A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).
First Author: Qing Zhou
Poster
2011 ASCO Annual Meeting
A phase I, single-institution open label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies.
First Author: S. R. Ahmed